STAAR Surgical notches regulatory milestones for its Visian Implantable Collamer Lenses, landing a rescheduled date with a panel of FDA advisors and winning Japanese approval for a new model. California ophthalmic devices maker STAAR Surgical (NSDQ:STAA) touted a pair of regulatory wins, landing a date with an FDA advisory panel and notching new Japanese market approval for its Visian Implantable Collamer Lens with CentraFLOW technology. STAAR will meet next week with the FDA's Ophthalmic Devices Panel to review the premarket approval application for the company's Visian Toric ICL for treatment of myopic astigmatism.
Help employers find you! Check out all the jobs and post your resume.
